NOT_YET_RECRUITING
I'm interested ...!!
Diabetic Cardiomyopathy and Heart Failure
This study will demonstrate the beneficial effects of ketone bodies in type 1 diabetes (T1D) patients and will have significant translational applications to prevent serious metabolic conditions such as T1D induced diabetic cardiomyopathy (DCM).
Conditions:
🦠 Diabetic Cardiomyopathies 🦠 Heart Failure
🗓️ Study Start (Actual) July 2023
🗓️ Primary Completion (Estimated) June 2026
✅ Study Completion (Estimated) June 2026
👥 Enrollment (Estimated) 40
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 Louisville, Kentucky, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • -Diabetic subjects with high blood glucose levels

    Exclusion Criteria:

    • - Comorbidities affecting glucose levels and cardiac function
Ages Eligible for Study: 18 Years to 70 Years (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 16 September 2022
  • First Submitted that Met QC Criteria 5 October 2022
  • First Posted 7 October 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 5 October 2022
  • Last Update Posted 7 October 2022
  • Last Verified October 2022
I'm interested ...!!